These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 4992052)

  • 21. Recall of isoniazid used for antimicrobial susceptibility testing for tuberculosis.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Sep; 49(34):780-2. PubMed ID: 10987246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mode of action of antituberculous agents and ultrastructure of mycobacteria.
    Oka S; Yamaguchi J; Ariji F; Madokoro K; Kumano N
    Sci Rep Res Inst Tohoku Univ Med; 1971 Jul; 18(1):7-13. PubMed ID: 5005200
    [No Abstract]   [Full Text] [Related]  

  • 23. [Molecular medicine and treatment of tuberculosis].
    Perel'man MI; Khomiakov IuN; Kiselev VI; Severin ES; Pal'tsev MA
    Probl Tuberk; 2001; (5):5-7. PubMed ID: 11588966
    [No Abstract]   [Full Text] [Related]  

  • 24. [Complex research studies in the testing of the effectiveness of phenaside].
    Sel'tsovskiĭ PP; Irtuganova OA; Slogotskaia LV; Smirnova NS; Moroz AM; Borzenko AS; Spasov AA; Smirnova LA; Dzhura PI; Karpov AV; Ivanovskiĭ VB; Pauker MN; Plemiannikova GI
    Probl Tuberk; 2001; (8):29-31. PubMed ID: 11767386
    [No Abstract]   [Full Text] [Related]  

  • 25. [Study of tuberculostatic activity and blood concentration of new agents--rifampicin and ethambutol--in patients with pulmonary tuberculosis].
    Mkrtchian SV; Ushkin VV
    Antibiotiki; 1971 May; 16(5):472-7. PubMed ID: 5002224
    [No Abstract]   [Full Text] [Related]  

  • 26. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
    Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
    J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Sodium metabisulfite inhibition of the reaction between isoniazid and streptomycin in solution].
    Aleksandrova AE; Moldaver BL; Borisova OA; Vishnevskiĭ BI; Il'ina TB
    Probl Tuberk; 1983 Aug; (8):54-7. PubMed ID: 6356127
    [No Abstract]   [Full Text] [Related]  

  • 28. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
    Grosset J; Truffot C; Fermanian J; Lecoeur H
    Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
    Hearn MJ; Cynamon MH
    Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Catalase activity of drug-resistant Mycobacterium tuberculosis strains].
    Smirnov VD
    Antibiotiki; 1971 Oct; 16(10):917-9. PubMed ID: 5003057
    [No Abstract]   [Full Text] [Related]  

  • 31. New approaches to the treatment of latent tuberculosis.
    Sterling TR
    Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isoniazid activity is terminated by bacterial persistence.
    Mitchison DA; Jindani A; Davies GR; Sirgel F
    J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis.
    Fattorini L; Gennaro R; Zanetti M; Tan D; Brunori L; Giannoni F; Pardini M; Orefici G
    Peptides; 2004 Jul; 25(7):1075-7. PubMed ID: 15245864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of isoniazid on the early tuberculous lesions in the mouse].
    Mauss H
    Rev Immunol Ther Antimicrob; 1968; 32(6):357-74. PubMed ID: 4975681
    [No Abstract]   [Full Text] [Related]  

  • 35. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis.
    Sriram D; Yogeeswari P; Yelamanchili Priya D
    Biomed Pharmacother; 2009 Jan; 63(1):36-9. PubMed ID: 18343086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Blood bacteriostatic activity in patients with respiratory tuberculosis].
    Manicheva OA; Vishnevskiĭ BI; Ivanova LI; Pavlova MV; Archakova LI
    Probl Tuberk; 2001; (8):24-6. PubMed ID: 11767384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 38. Prevalence of S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut.
    Ahmad S; Fares E; Araj GF; Chugh TD; Mustafa AS
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):920-6. PubMed ID: 12365580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simplified screening test for phenotyping of isoniazid inactivators.
    Eidus L; Hodgkin MM
    Int J Clin Pharmacol; 1973 Feb; 7(1):82-6. PubMed ID: 4699389
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.